Treatment-refractory depression
Conditions
Interventions
Sponsors
The Affiliated Brain Hospital of Guangzhou Medical University (Guangzhou Huiai Hospital)
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Patients group: 1. Be able to communicate and provide written consent; 2. Diagnosis of major depression identified by treating psychiatrists and confirmed via a checklist of Diagnostic and Statistical Manual of Mental Disorders-4th edition (DSM-IV) criteria; TRD defined as an insufficient therapeutic response to >=2 adequate antidepressants treatment trials during the current episode; 3. Male and female patients aged 18–65 years; 4. A total score of >= 17 on the 17-item Hamilton Rating Scale for Depression (HAMD-17) at screening; 5. Participants must have junior middle school and above years of schooling; 6. Han Chinese patients, right handedness. Healthy control group 1. The subjects or their relatives of the third generation of two lineages did not meet any diagnostic criteria of mental illness in DSM-IV, and were not related to the patients group; The other criteria were 4-6.
Exclusion criteria
Exclusion criteria: Patients group: (1) Other major psychiatric disorders that meet the DSM-IV diagnostic criteria include organic mental disorders, alcohol dependence, drug dependence/abuse, schizophrenia, etc; (2) Currently, there are serious and unstable somatic diseases such as diabetes, thyroid disease, hypertension, heart disease and narrow-angle glaucoma, etc; Wechsler intelligence test (WAIS-RC) full scale IQ (FIQ) total scores <= 80; (3) A history of neurological diseases such as epilepsy and dementia; (4) Subjects with metal in the body, such as pacemaker or brain electrode; (5) Previous history of anesthetics allergy; (6) Women who are at the stage of pre-pregnancy, pregnancy or lataction; (7) Contraindications to MRI or intolerant of MRI scanning environment, such as claustrophobia. Healthy control group: the same as the patient group. The age, gender and years of education were matched with the patients group.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| safety;tolerability;Efficacy; | — |
Countries
China
Contacts
Public ContactZheng Wei
Outcome results
None listed